Combination comprising zidovudine and an antimicrobial compound
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11951119-B2
Publication Date
2024-04-09
Expiration Date
Abstract
The invention provides a combination comprising zidovudine or a pharmaceutically acceptable derivative thereof and an antimicrobial compound selected from nitrofurantoin, mecillinam, fosfomycin, cephalexin and faropenem, or a pharmaceutically acceptable derivative or prodrug thereof. These combinations are particularly useful for the treatment of microbial infections.
Core Innovation
The disclosed subject matter describes combinations of zidovudine (AZT) or a pharmaceutically acceptable salt and/or solvate thereof with an antimicrobial compound selected from nitrofurantoin, mecillinam, fosfomycin, cephalexin and faropenem, including corresponding pharmaceutically acceptable salts and/or solvates and prodrug thereof. The combinations are presented for treatment of microbial infections.
The document emphasizes an unexpected synergistic antimicrobial effect, described as greater-than-additive, when AZT is combined with the selected antimicrobial compounds. Synergy is assessed against log phase (multiplying) microorganisms and also involves references to clinically latent microorganisms.
The disclosure further addresses formulations and related chemical forms for the components, including definitions covering targeted microbes and conditions, and coverage of pharmaceutical compositions, prodrugs/derivatives, salts/solvates, and stereoisomer/isotopic variations.
Claims Coverage
The provided independent claims cover three main inventive concepts: (i) a composition combining AZT with a selected antimicrobial from a defined group; (ii) a pharmaceutical composition that further includes a pharmaceutically acceptable adjuvant, diluent or carrier; and (iii) a product comprising AZT with the selected antimicrobial from the same defined group. Across the independent claims, the inventive features focus on the specific combination pairing and the defined selection of antimicrobial members, including salts/solvates/prodrug forms.
Zidovudine paired with a defined antimicrobial group
A composition comprising zidovudine or a pharmaceutically acceptable salt and/or solvate thereof and an antimicrobial compound selected from the group consisting of nitrofurantoin, mecillinam, fosfomycin, cephalexin and faropenem, or a pharmaceutically acceptable salt and/or solvate or prodrug thereof.
Pharmaceutical composition with AZT, defined antimicrobial, and pharmaceutically acceptable carrier components
A pharmaceutical composition comprising zidovudine or a pharmaceutically acceptable salt and/or solvate thereof in combination with an antimicrobial compound selected from the group consisting of nitrofurantoin, mecillinam, fosfomycin, cephalexin and faropenem or a pharmaceutically acceptable salt and/or solvate or prodrug thereof, and a pharmaceutically acceptable adjuvant, diluent or carrier.
Product comprising AZT and a defined antimicrobial group
A product comprising zidovudine or a pharmaceutically acceptable salt and/or solvate thereof and an antimicrobial compound selected from the group consisting of nitrofurantoin, mecillinam, fosfomycin, cephalexin and faropenem or a pharmaceutically acceptable salt and/or solvate or prodrug thereof.
Across the independent claims, the core claim coverage is the defined combination of zidovudine (including salts/solvates) with one of nitrofurantoin, mecillinam, fosfomycin, cephalexin, and faropenem (including salts/solvates/prodrug forms). One independent claim further requires inclusion of a pharmaceutically acceptable adjuvant, diluent or carrier, while the remaining independent claims focus on the same AZT/antimicrobial pairing.
Stated Advantages
Provides an unexpected synergistic antimicrobial effect described as greater-than-additive.
Documented Applications
Treatment of microbial infections, particularly Gram-negative bacterial infections such as urinary tract infections.
Synergy assessment for log phase (multiplying) microorganisms and references to clinically latent microorganisms.
Interested in licensing this patent?